On the Russian retail pharmaceutical market, a total of 115.6 million packs of anti-ulcer medicines (EphMRA group A02B) were sold in January–October 2025, amounting to RUB 25.0 billion at retail prices, including VAT. According to the Retail Drug Sales Audit in Russia (total sell out) database of the analytical company RNC Pharma, sales growth compared to the same period of 2024 reached 5.4% in physical terms (packs), while value growth amounted to 15.9%. Similar dynamics were observed in previous years: in 2024 versus 2023, value sales increased by 15.6%, while physical consumption grew by 2.9%; in 2023 versus 2022, the respective indicators stood at 15.5% and 5.4%.

The largest volumes of anti-ulcer medicine consumption are concentrated in Moscow, the Moscow Region and Krasnodar Krai. Taken together, these three regions accounted for 22.5% of the market in value terms and 17.4% in physical terms. At the same time, while Moscow and the Moscow Region demonstrated positive physical growth of +4.0% and +4.6% respectively compared to January–October 2024, demand in Krasnodar Krai declined slightly, by 0.1% in packs. Overall, a decrease in physical consumption was recorded in only eight Russian regions during the analysed period. The absolute leader in per-capita consumption was Sakhalin Region: on average, each resident spent around RUB 243 on medicines for the treatment of acid-related diseases. This result is driven not only by regional pricing specifics — physical consumption per capita there exceeds the national average by more than 40%.

The backbone of the anti-ulcer medicines group is formed by omeprazole-based products, although the category as a whole includes 20 international non-proprietary names (INNs), including combinations. As expected, unbranded omeprazole products lead the brand ranking: in January–October 2025 they were represented by 27 different companies. However, these products showed relatively modest dynamics, with value sales increasing by only 10% year on year. Second place in the category is held by Omez from Dr. Reddy’s, which accounts for more than 13% of the market and demonstrated growth of 16%, in line with the category average. Rebagiт by PRO.MED.CS ranks third with an 11% market share, while its value sales increased by 20% over the year.

The absolute record-holder in terms of value growth was De-Nol by Cheplapharm (+46%), although this is largely attributable to supply disruptions in 2023–2024 caused by a change of ownership and the need to re-register the product. Among branded products, Razo by Dr. Reddy’s also demonstrated strong growth (+24% in value terms), supported by active promotion. However, the highest growth rates were recorded for branded generics: sales of rebamipide-based products increased by 39% year on year, with Northern Star accounting for the bulk of volumes. The second-highest growth was observed for pantoprazole-based products (+35%), led by Ozon Pharmaceuticals.

Table. TOP-10 Brands of Anti-Ulcer Medicines (EphMRA Group A02B) by Value Sales on the Russian Retail Pharmaceutical Market, January–October 2025